Last $4.80 USD
Change Today +0.05 / 1.05%
Volume 189.5K
PACB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:13 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

pacific biosciences of calif (PACB) Key Developments

Pacific Biosciences of California, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014

Pacific Biosciences of California, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $11,425,000, operating loss of $18,302,000, net loss of $19,136,000 or $0.27 per basic and diluted share compared to the total revenue of $6,048,000, operating loss of $19,997,000, net loss of $20,471,000 or $0.33 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported total revenue of $23,067,000, operating loss of $36,547,000, net loss of $38,022,000 or $0.55 per basic and diluted share compared to the total revenue of $11,626,000, operating loss of $40,604,000, net loss of $41,575,000 or $0.7 per basic and diluted share for the same period a year ago.

Pacific Biosciences of California, Inc., Q2 2014 Earnings Call, Jul 24, 2014

Pacific Biosciences of California, Inc., Q2 2014 Earnings Call, Jul 24, 2014

Pacific Biosciences and GenDx Initiate Co-Marketing Activities for Full-Length HLA Gene Sequencing Products

Pacific Biosciences of California, Inc., and GenDx announced a co-marketing agreement to offer products for full-length HLA gene sequencing. The Human Leukocyte Antigen (HLA) system consists of a large family of highly variable genes and allelic variants that forms the basis of the human immune system. High-resolution HLA typing and sequencing of the complete gene enables determination of even the smallest variations between HLA alleles. HLA allele-specific genotyping is critical for autoimmune disease-association studies, drug hypersensitivity research and other applications. Thus, there has been an ever growing interest in characterizing the HLA genes in their entirety. GenDx, which currently offers reagents for the amplification of full-length, Class I HLA genes, will offer a version of its NGSgo(R) reagent line with barcoded primers developed with Pacific Biosciences for sequencing on the PacBio RS II DNA sequencing system. Using the GenDx NGSengine(R) software package to analyze data from the PacBio system provides customers with a highly accurate, allele-level HLA typing solution. This new reagent kit will allow the pooling of full-length, Class I HLA genes from multiple samples into a single sequencing run.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Year 2014

Pacific Biosciences of California, Inc. announced that it will be providing an update to 2014 financial forecast. Starting with revenue, the company is increasing revenue growth forecast for the year, from 55% previously to approximately 70%, which translates a total annual revenue estimate of between $47 million and $48 million for 2014.

Pacific Biosciences of California, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2014

Pacific Biosciences of California, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2014. For the quarter, revenue for totaled $11.6 million, compared to $5.6 million for the first quarter of 2013. First quarter 2014 revenue reflects the installation of nine PacBio(R) RS II systems, compared to three PacBio(R) RS systems during the first quarter of 2013. Total revenue for the first quarter of 2014 also included $1.7 million of revenue recognized pursuant to a development agreement the company entered into with Roche Diagnostics during September 2013. The net loss for the first quarter of 2014 was $18.9 million or $0.28 per basic and diluted share compared to $21.1 million or $0.37 per basic and diluted share for the first quarter of 2013. Operating loss was $18.245 million compared to $20.607 million reported a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PACB:US $4.80 USD +0.05

PACB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $8.34 USD -0.04
Fluidigm Corp $26.93 USD -0.50
IntelliCell BioSciences Inc $0.0016 USD 0.00
Luminex Corp $17.41 USD -0.33
Sequenom Inc $3.72 USD +0.05
View Industry Companies
 

Industry Analysis

PACB

Industry Average

Valuation PACB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.5x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIFIC BIOSCIENCES OF CALIF, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.